Linagliptin is Used for treating type 2 diabetes, especially in patients with renal impairment and insufficient glycemic control. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Tradjenta on May 2, 2011. 3 different companies have introduced drugs containing Linagliptin.

Linagliptin Patents

Given below is the list of patents protecting Linagliptin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Tradjenta	US10034877	Treatment for diabetes in patients inappropriate for metformin therapy	Aug 05, 2029	Boehringer Ingelheim
Tradjenta	US10034877 (Pediatric)	Treatment for diabetes in patients inappropriate for metformin therapy	Feb 05, 2030	Boehringer Ingelheim
Tradjenta	US11033552	DPP IV inhibitor formulations	May 04, 2027	Boehringer Ingelheim
Tradjenta	US11033552 (Pediatric)	DPP IV inhibitor formulations	Nov 04, 2027	Boehringer Ingelheim
Tradjenta	US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	Apr 10, 2030	Boehringer Ingelheim
Tradjenta	US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	Apr 24, 2017 (Expired)	Boehringer Ingelheim
Tradjenta	US6890898	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Tradjenta	US7078381	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Tradjenta	US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May 02, 2025	Boehringer Ingelheim
Tradjenta	US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Nov 02, 2025	Boehringer Ingelheim
Tradjenta	US7459428	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Tradjenta	US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug 12, 2023 (Expired)	Boehringer Ingelheim
Tradjenta	US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug 12, 2023 (Expired)	Boehringer Ingelheim
Tradjenta	US8673927	Uses of DPP-IV inhibitors	May 04, 2027	Boehringer Ingelheim
Tradjenta	US8673927 (Pediatric)	Uses of DPP-IV inhibitors	Nov 04, 2027	Boehringer Ingelheim
Tradjenta	US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun 04, 2030	Boehringer Ingelheim
Tradjenta	US8846695 (Pediatric)	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Dec 04, 2030	Boehringer Ingelheim
Tradjenta	US8853156	Treatment for diabetes in patients inappropriate for metformin therapy	Mar 05, 2031	Boehringer Ingelheim
Tradjenta	US8853156 (Pediatric)	Treatment for diabetes in patients inappropriate for metformin therapy	Sep 05, 2031	Boehringer Ingelheim
Tradjenta	US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov 26, 2025	Boehringer Ingelheim
Tradjenta	US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	May 26, 2026	Boehringer Ingelheim
Tradjenta	US9173859	Uses of DPP IV inhibitors	May 04, 2027	Boehringer Ingelheim
Tradjenta	US9486526	Treatment for diabetes in patients inappropriate for metformin therapy	Aug 05, 2029	Boehringer Ingelheim
Tradjenta	US9486526 (Pediatric)	Treatment for diabetes in patients inappropriate for metformin therapy	Feb 05, 2030	Boehringer Ingelheim

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Linagliptin's patents.

Latest Legal Activities on Linagliptin's Patents

Given below is the list recent legal activities going on the following patents of Linagliptin.

Event	Date	Patent/Publication
Today's Critical Events
Payment of Maintenance Fee, 8th Year, Large Entity	02 May, 2024	US9486526
Payment of Maintenance Fee, 8th Year, Large Entity	30 Mar, 2022	US8853156(Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity	25 Jan, 2022	US10034877
Payment of Maintenance Fee, 4th Year, Large Entity	29 Apr, 2020	US9486526
Recordation of Patent Grant Mailed	31 Jul, 2018	US10034877
Patent Issue Date Used in PTA Calculation	31 Jul, 2018	US10034877
Email Notification	13 Jul, 2018	US10034877
Issue Notification Mailed	11 Jul, 2018	US10034877
Dispatch to FDC	02 Jul, 2018	US10034877
Mail Miscellaneous Communication to Applicant	12 Jun, 2018	US10034877

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳